We are trailblazers, tenaciously deciphering human biology.

Martin Reese, Ph.D.

Co-Founder, President, and CEO

Dr. Reese is an internationally recognized expert and entrepreneur in Genomics and Bioinformatics. Prior to founding Fabric Genomics, Martin served as Vice President of Discovery Informatics for ValiGen, and co-founded Neomorphic, where he served as President and Chief Scientific Officer. The human genome annotation software that Martin developed at Neomorphic, provided the foundation for the successful commercialization of microarrays by Affymetrix. During his career he has been actively involved in community-wide assessments of genome annotation. He organized the state-of-the-art Genome Annotation Assessment Project and was a member of the Berkeley Drosophila Genome Project, which provided the essential proof-of-concept platform for “shotgun” sequencing technology. At the Lawrence Berkeley National Laboratories Martin developed gene-finding algorithms for the Human Genome Project. He holds a Masters degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly from the University of Hohenheim, Germany and the University of California, Berkeley.

Paul Billings, M.D., Ph.D.

Co-Founder and Acting Chief Medical Officer

Dr. Billings serves as Chief Medical Officer at Fabric Genomics. Prior to joining Fabric Genomics, Dr. Billings was CMO at Life Technologies, acquired by Thermo Fisher Scientific, Inc. (NYSE: TMO). Before that he was founding and acting Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital. Dr. Billings served as President, CEO and Director of CELLective Dx Corporation. Dr. Billings currently serves on the Scientific Advisory Board of the FDA, the Genomic Medicine Advisory Committee at the Dept. of Veterans Affairs, and the National Academy of Sciences Institute of Medicine’s Roundtable on Genomics. He was Deputy Chief of Staff and Chief of General Medicine at the Palo Alto VA Healthcare System and Stanford Medical School, and then CMO and Deputy Network Director of VISN 17 in the Department of Veterans Affairs. He has been Professor of Anthropology (adjunct) at UC Berkeley and has published extensively on topics in immunology, genetics and medicine. Dr. Billings received an A.B. summa cum laude from UC San Diego, and both his M.D. and Ph.D. degrees from Harvard University.

Charlene Son Rigby

Chief Business Officer

Charlene is responsible for customer success, business development and regulatory at Fabric Genomics. Charlene has spent her career building businesses at the intersection of data, technology and life sciences. Previous to Fabric Genomics, she was responsible for all go-to-market activities at Metamarkets, a big data analytics startup. Prior to Metamarkets, Charlene was Vice President of Business Planning at Oracle where she rolled out Analytics for the sales organization, and Executive Director of Sales Operations at Siebel Systems, a $2B license business. She also led product management at DoubleTwist, a bioinformatics startup. Charlene started her career as a neuroscience researcher at Syntex (acquired by Roche). She holds a B.A. in Human Biology from Stanford University and an M.B.A. from the Haas School of Business at U.C. Berkeley.

Ivy Chan

Chief Financial Officer

Ivy is the Chief Financial Officer at Fabric Genomics, overseeing global finance, accounting, and HR functions. Ivy joins Fabric Genomics with two decades of financial leadership experience at notable companies, serving as finance steward at TIBCO and Marketo. Most recently as CFO of tibbr and Loyalty Lab, business units at TIBCO, Ivy was responsible for building out the SaaS-based business prior to the company’s acquisition by Vista Equity Partners. As the finance and sales operations business partner at Marketo, she led sales finance by building the field processes and sales performance analytics that met the needs of a hyper-growth organization and saw the company through a successful IPO in 2013. Prior to joining Marketo, Ivy held finance positions at other leading technology companies including SAP and Apple. She graduated from U.C. Berkeley with a B.A. in Economics and an M.B.A. from the Haas School of Business.

Francisco De La Vega

Senior Vice President, Genomics

Francisco is a geneticist and computational biologist with interests in clinical and population genomics. After spending over a decade at Applied Biosystems/Life Technologies, where he played a pivotal role in the development of several successful genetic analysis products, he has more recently contributed to start-up companies in focused on bringing NGS into the clinic. Francisco is Adjunct Professor in the Department of Biomedical Data Science of the Stanford School of Medicine, a Director of the International Society of Computational Biology, and has been a member of the NIST Genome-in-a-Bottle Consortium, the PanCancer Analysis of Whole Genomes project of the ICGC, and the Steering Committee of the 1000 Genomes Project. In 2009 he was inducted to the Innovation & Invention Society of Life Technologies, a program that recognized the company’s most elite inventors, and in 2008 was a co-recipient of the Bio-IT World Best Practices Award in Basic Research. Francisco received his Doctor of Science degree in Genetics and Molecular Biology from CINVESTAV, the leading research and post-graduate education institution of Mexico.

Marco Falcioni

Vice President, Development

John Stuelpnagel, D.V.M.

Co-Founder, Chairman of the Board of Directors

Dr. Stuelpnagel currently serves as the Executive Chairman of Ariosa Diagnostic since 2009 and a board member at Sequenta, two leading genomic-based Diagnostic companies in the San Francisco bay area. Prior to this, John co-founded Illumina Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and biological function.
John was involved in making Illumina one of the most successful life science companies, serving as its first President and Chief Executive Officer from 1998 to 1999, Vice President of Business Development from 1999 to 2002, Senior Vice President of Operations from 2002 to 2005 and Chief Operating Officer from January 2005 to April 2008.
Prior, he was a venture capitalist at CW Group from 1997 to 1998 and with Catalyst Partners, a venture capital firm, from 1996 to 1997. While at CW Group, John uncovered what would become Illumina’s BeadArray technology at Tufts University and negotiated an exclusive license to that technology which led to the founding of Illumina Inc. He also served as a member of the Board of Directors of Illumina Inc. from April 1998 until April 2008. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.

Mike A. Aicher

Board of Directors

Mike co-founded and served as National Genetics Institute’s (NGI) CEO since 1991. NGI became a wholly owned subsidiary of Laboratory Corporation of America (NASDAQ: LH) in 2000, where he held various positions.
He ran the company’s “Esoteric Business Units”, which generated over $1 billion in annual revenue. Mike holds a Bachelor of Science in Business Administration from the University of Redlands, a Master of Business Administration in Economics from Columbus University and is a certified Global Biotechnology Executive from the University of California, Berkeley. He also received Ernst and Young’s “Entrepreneur of the Year” award for emerging technologies.

Tad Buchanan

Board of Directors

Tad co-founded the investment firm of Buchanan Investments, Inc. in 1998 with his father, Mike. Together, they have founded, invested in and raised equity and debt capital for numerous companies, including DM&E Railroad, Central Montana Resources, Opti Canada, White Oak Resources, AlphaClone, TabletCommand, Gensys Software, Tri Alpha Energy, OneSun Solar, and numerous other private companies.
Prior to founding Buchanan Investments, Inc., Tad was an Executive Director at UBS Securities with primary responsibility for managing Asian equity sales and trading based in NY. He was also an equity analyst at UBS and W.I. Carr (Far East), Ltd. based in Hong Kong, with responsibility for covering financial services, software, industrial and energy companies in Indonesia, Thailand, India, Pakistan, Sri Lanka and Bangladesh. Prior to joining W.I. Carr (Far East) Ltd., Tad was a credit analyst within the Corporate Lending Group of Wells Fargo Bank. He graduated from Pepperdine University with a B.A. in Economics and from Boston College with an M.B.A, International Finance. He currently serves on the boards of Central Montana Resources, AlphaClone, Tablet Command, and OneSun Solar. Tad is also a board observer of Tri Alpha Energy. He is married with three children, and is a Trustee of Marin Country Day School in Corte Madera, CA.

Matt Posard

Board of Directors

Matt has over 25 years of general management and commercial experience in the life sciences, molecular diagnostics and genomics industry. Mr. Posard held influential leadership roles with market leading companies including Illumina, Trovagene, Biosite / Alere, and Gen-Probe.
Matt has a distinguished reputation in commercializing transformative novel products and technology in the genomics space. Mr. Posard holds a B.A. degree in Quantitative Economics and Decision Science from the University of California, San Diego and currently serves as a board member for Halozyme Therapeutics, SlipChip Corporation, Dermtech Inc., and Envision Genomics.

Edward Kiruluta

Co-Founder, Fabric Genomics

Mark Yandell, PhD

University of Utah & USTAR Center for Genetic Discovery

Thomas Quertermous, MD

Stanford University Cardiovascular Medicine & VIA Pharmaceuticals

Paul Flicek, DSc

European Bioinformatics Institute

Joshua Schiffman, MD

University of Utah School of Medicine & Huntsman Cancer Institute

Gholson Lyon, MD, PhD

Institute for Basic Research in Developmental Disabilities (IBR)

Geoffrey S. Ginsburg, MD, PhD

Duke Center for Applied Genomics and Precision Medicine & Global Genomic Medicine Collaborative

Leroy Hood, MD, PhD

Institute for Systems Biology & University of Washington